ArticleRSC advances2024
MolToxPred: small molecule toxicity prediction using machine learning approach.
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- A benchmark dataset and interpretable deep learning framework for drug-induced developmental neurotoxicity prediction.RSC advances · 2026Article
- AI/ML-based computational models for toxicity prediction.Environmental science and pollution research international · 2026Review
- Domain-generalized representation learning for cross-chemical-family toxicity prediction.Scientific reports · 2026Article
- Toxicodynamics and Human Health Risks of Metal Nanoparticles: A Review of AI/ML-Based Predictive Nanotoxicology.International journal of nanomedicine · 2026Review
- Application and Prospects of Large Language Models in Small-Molecule Drug Discovery.Analytical chemistry · 2025Review
- Drug toxicity prediction based on genotype-phenotype differences between preclinical models and humans.EBioMedicine · 2025Article
- ProToxin, a Predictor of Protein Toxicity.Toxins · 2025Article
- ACLPred: an explainable machine learning and tree-based ensemble model for anticancer ligand prediction.Scientific reports · 2025Article
- A scoping review of artificial intelligence applications in clinical trial risk assessment.NPJ digital medicine · 2025Article
- TFProtBert: Detection of Transcription Factors Binding to Methylated DNA Using ProtBert Latent Space Representation.International journal of molecular sciences · 2025Article
- Prediction of ADMET profile and anti-inflammatory potential of chamuangone.Scientific reports · 2025Article
- Article
- Hybrid Class Balancing Approach for Chemical Compound Toxicity Prediction.Current computer-aided drug design · 2025Article
- The Present State and Potential Applications of Artificial Intelligence in Cancer Diagnosis and Treatment.Recent patents on anti-cancer drug discovery · 2025Review
- AISMPred: A Machine Learning Approach for Predicting Anti-Inflammatory Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2024Article
- MvMRL: a multi-view molecular representation learning method for molecular property prediction.Briefings in bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Different types of chemicals and products may exhibit various health risks when administered into the human body. For toxicity reasons, the number of new drugs entering the market through the conventional drug development process has been reduced over the years. However, with the advent of big data and artificial intelligence, machine learning techniques have emerged as a potential solution for predicting toxicity and ensuring efficient drug development and chemical safety. An ML model for toxicity prediction can reduce experimental costs and time while addressing ethical concerns by drastically reducing the need for animals and clinical trials. Herein, MolToxPred, an ML-based tool, has been developed using a stacked model approach to predict the potential toxicity of small molecules and metabolites. The stacked model consists of random forest, multi-layer perceptron, and LightGBM as base classifiers and Logistic Regression as the meta classifier. For training and validation purposes, a comprehensive set of toxic and non-toxic molecules is curated. Different structural and physicochemical-based features in the form of molecular descriptors and fingerprints were employed. MolToxPred utilizes a comprehensive feature selection process and optimizes its hyperparameters through Bayesian optimization with stratified 5-fold cross-validation. In the evaluation phase, MolToxPred achieved an AUROC of 87.76% on the test set and 88.84% on an external validation set. The McNemar test was used as the post-hoc test to determine if the stacked models' performance was significantly different compared to the base learners. The developed stacked model outperformed its base classifiers and an existing tool in the literature, reaffirming its better performance. The hypothesis is that the incorporation of a diverse set of data, the subsequent feature selection, and a stacked ensemble approach give MolToxPred the edge over other methods. In addition to this, an attempt has been made to identify structural alerts responsible for endpoints of the Tox21 data to determine the association of a molecule with a plausible downstream pathway of action. MolToxPred may be helpful for drug discovery and regulatory pipelines in pharmaceutical and other industries for
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.